Gut-derived incretin hormones and new therapeutic approaches

被引：18

作者：

Bloomgarden, AT

机构：

来源：

DIABETES CARE | 2004年 / 27卷 / 10期

关键词：

D O I：

10.2337/diacare.27.10.2554

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：2554 / 2559

页数：6

共 17 条

[1] Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes [J].

Ahrén, B ;

Landin-Olsson, M ;

Jansson, PA ;

Svensson, M ;

Holmes, D ;

Schweizer, A .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (05) :2078-2084

[2] Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes [J].

Ahrén, B ;

Simonsson, E ;

Larsson, H ;

Landin-Olsson, M ;

Torgeirsson, H ;

Jansson, PA ;

Sandqvist, M ;

Båvenholm, P ;

Efendic, S ;

Eriksson, JW ;

Dickinson, S ;

Holmes, D .

DIABETES CARE, 2002, 25 (05) :869-875

[3]

CREUTZFELDT W, 1983, SCAND J GASTROENTERO, V18, P111

[4] BOTH SUBCUTANEOUSLY AND INTRAVENOUSLY ADMINISTERED GLUCAGON-LIKE PEPTIDE-I ARE RAPIDLY DEGRADED FROM THE NH2-TERMINUS IN TYPE-II DIABETIC-PATIENTS AND IN HEALTHY-SUBJECTS [J].

DEACON, CF ;

NAUCK, MA ;

TOFTNIELSEN, M ;

PRIDAL, L ;

WILLMS, B ;

HOLST, JJ .

DIABETES, 1995, 44 (09) :1126-1131

[5] One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and α- and β-cell function and reduces endogenous glucose release in patients with type 2 diabetes [J].

Degn, KB ;

Juhl, CB ;

Sturis, J ;

Jakobsen, G ;

Brock, B ;

Chandramouli, V ;

Rungby, J ;

Landau, BR ;

Schmitz, O .

DIABETES, 2004, 53 (05) :1187-1194

[6] Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes [J].

Juhl, CB ;

Hollingdal, M ;

Sturis, J ;

Jakobsen, G ;

Agerso, H ;

Veldhuis, J ;

Porksen, N ;

Schmitz, O .

DIABETES, 2002, 51 (02) :424-429

[7] Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration [J].

Knudsen, LB ;

Nielsen, PF ;

Huusfeldt, PO ;

Johansen, NL ;

Madsen, K ;

Pedersen, FZ ;

Thogersen, H ;

Wilken, M ;

Agerso, H .

JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (09) :1664-1669

[8] Synthetic exendin-4 (Exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes [J].

Kolterman, OG ;

Buse, JB ;

Fineman, MS ;

Gaines, E ;

Heintz, S ;

Bicsak, TA ;

Taylor, K ;

Kim, D ;

Aisporna, M ;

Wang, Y ;

Baron, AD .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (07) :3082-3089

[9] The 3D structure of rat DPPIV/CD26 as obtained by cryo-TEM and single particle analysis [J].

Ludwig, K ;

Yan, SL ;

Fan, H ;

Reutter, W ;

Böttcher, C .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2003, 304 (01) :73-77

[10] Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26 [J].

Marguet, D ;

Baggio, L ;

Kobayashi, T ;

Bernard, AM ;

Pierres, M ;

Nielsen, PF ;

Ribel, U ;

Watanabe, T ;

Drucker, DJ ;

Wagtmann, N .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (12) :6874-6879

← 1 2 →